miRNAs for Prognosis and Prediction of Metastases
These biomarkers offer three benefits which are key to clinical and commercial success:1. Multiple applications - Novel, proprietary biomarkers for diagnosis, prognosis and monitoring of CRC 2. Stand-alone or multiplexed - The biomarkers can potentially be used in stand-alone assays, or as part of multiplexed assays to achieve greater sensitivity and specificity3. Integration ΓÇô The biomarkers are compatible with standard molecular platforms and workflows
ΓÇó Cancer screeningΓÇó Differential diagnosis between colorectal cancer with metastasis and without metastasisΓÇó Planning of cancer treatmentΓÇó Evaluation of cancer prognosisΓÇó Monitoring of patients during and after treatmentΓÇó Surveillance in high risk patients (e.g. hereditary predisposition)ΓÇó Cancer research, including clinical developmentΓÇó Development of blood-based assays
None
美国
